TABLE 3.3.

Comparison between therapies – quantitative analysis.

	CLET (Holoclar®)	SLET
Up-front cost of therapy	€ 93,907 (cost of surgery)	€ 21,000
Long-term healthcare costs
Long-term stability**	23.4% failures up to 10 years (based on a proven follow-up)	24.8% failures up to 4 years (based on a proven 4 years follow-up) + 6 years hypothetical stability (best case) Or 6 years potential 100% failure (worst case)
Total potential cost of failures § in 10 years (follow-up)	€ 206,802	€ 220,943–€ 618,639
Total potential partial cost including surgery	€ 300,709	€ 241,943–€ 639,639

In this table, the percentage of failure has been calculated from Rama et al. (2010) for Holoclar^® and Basu et al. (2016) for SLET. **Failure rate and long-term stability were calculated on reported successful outcomes and proven 10 years follow-up for Holoclar^® (Rama et al., 2010), and 4 years follow-up reported for SLET (Basu et al., 2016). The following 6 years (required to compare the data with ATMP) of SLET have been considered as a range: from a best case scenario as stable percentage of failure (24.8%) (Basu et al., 2016) to the worst case of late failure (100%). ^§ The cost of failure was based on expenses for Best Supportive Care (BSC in Table 3.1).